

# Analysis of Lung Flute–collected Sputum for Lung Cancer Diagnosis

Jian Su<sup>1</sup>, Nigar Anjuman<sup>1</sup>, Maria A. Guarnera<sup>1</sup>, Howard Zhang<sup>2</sup>, Sanford A. Stass<sup>1</sup> and Feng Jiang<sup>1</sup>

<sup>1</sup>Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA. <sup>2</sup>Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.

**ABSTRACT:** Molecular analysis of sputum can help diagnose lung cancer. We have demonstrated that Lung Flute can be used to collect sputum from individuals who cannot spontaneously expectorate sputum. The objective of this study is to further evaluate the performance of the Lung Flute by comparing the characteristics of parallel samples collected with and without the Lung Flute and the usefulness for diagnosis of lung cancer. Fifty-six early-stage lung cancer patients (40 current smokers and 16 former smokers) and 73 cancer-free individuals (52 current smokers and 21 former smokers) were instructed to spontaneously cough and use Lung Flute for sputum sampling. Sputum cytology and polymerase chain reaction analysis of three miRNAs (miRs-21, 31, and 210) were performed in the specimens. All 92 current smokers and 11 (28.7%) of 37 former smokers spontaneously expectorated sputum and also produced sputum when using the Lung Flute. Twenty-seven former smokers (70.3%) who could not spontaneously expectorate sputum, however, were able to produce sputum when using the Lung Flute. The specimens were of low respiratory origin without contamination from other sources, eg, saliva. There was no difference of sputum volume and cell populations, diagnostic efficiency of cytology, and analysis of the miRNAs in the specimens collected by the two approaches. Analysis of the sputum miRNAs produced 83.93% sensitivity and 87.67% specificity for identifying lung cancer. Therefore, sputum collected by the Lung Flute has comparable features as spontaneously expectorated sputum. Using the Lung Flute enables former smokers who cannot spontaneously expectorate to provide adequate sputum to improve sputum collection for lung cancer diagnosis.

**KEYWORDS:** Lung Flute, sputum, genes, lung tumor, diagnosis

**CITATION:** Su et al. Analysis of Lung Flute–collected Sputum for Lung Cancer Diagnosis. *Biomarker Insights* 2015;10 55–61 doi: 10.4137/BMI.S26883.

**RECEIVED:** April 02, 2015. **RESUBMITTED:** May 24, 2015. **ACCEPTED FOR PUBLICATION:** May 26, 2015.

**ACADEMIC EDITOR:** Karen Pulford, Editor in Chief

**TYPE:** Original Research

**FUNDING:** This work was supported in part by NCI R01CA161837, VA merit Award I01 CX000512, LUNGeVity/Upstage Foundation Early Detection Award, and Award from the Geaton and JoAnn DeCesaris Family Foundation (F.J.) and 5U24CA11509 (S.S.). The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.

**COMPETING INTERESTS:** Authors disclose no potential conflicts of interest.

**CORRESPONDENCE:** fjiang@som.umaryland.edu

**COPYRIGHT:** © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

Paper subject to independent expert blind peer review by minimum of two reviewers. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Published by Libertas Academica. Learn more about this journal.

## Introduction

Cigarette smoking is the highest single risk factor for lung cancer.<sup>1</sup> With the reduction in the prevalence of smoking, lung cancer has become more frequent among former smokers than current smokers.<sup>2</sup> For instance, in a cohort study of more than 5,000 patients whose lung cancer was diagnosed between 1997 and 2002, only 25% were current smokers and more than 60% were former smokers.<sup>2</sup> An National Cancer Institute (NCI)-National Lung Screening Trail showed that the early detection of lung cancer by using low-dose computed tomography (LDCT) followed by appropriate treatments significantly reduced the mortality.<sup>3</sup> Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Therefore, LDCT is recently recommended to be used for NSCLC screening in smokers.<sup>4</sup> The computed tomography (CT) scan has dramatically increased the number of indeterminate pulmonary nodules in asymptomatic smokers. However, 96.4% of the pulmonary nodules were ultimately confirmed as false positives.<sup>5</sup> Therefore, LDCT screening for lung cancer has a low specificity.<sup>5,6</sup> Radiology-based noninvasive and biopsy-based invasive techniques are presently used for the management of

CT-discovered indeterminate pulmonary nodules.<sup>7</sup> Yet the non-invasive approaches may cause unnecessary procedures, radiation exposure, anxiety, and cost. Furthermore, biopsies have risks of pneumothorax, hemorrhage, and false-negative results. Therefore, it is imperative to develop noninvasive approaches that can supplement LDCT for the diagnosis of NSCLC.<sup>5</sup>

Sputum is an easily available fluid that comprises exfoliated airway epitheliums of the lungs.<sup>8</sup> Cytological study of sputum can detect morphological abnormalities of bronchial epithelial cells under microscopy. However, the sensitivity of sputum cytology is very poor.<sup>9</sup> Studying sputum by using molecular approaches could detect cancer-related abnormalities that cannot be found under microscopy, thus presenting a potential tool for the diagnosis of NSCLC.<sup>10–12</sup> For example, we previously found that expression levels of 13 miRNAs (miRs-21, 31, 126, 143, 155, 182, 200b, 205, 210, 372, 375, 486, and 708) in sputum were associated with lung cancer.<sup>13–17</sup> We further developed a set of sputum miRNA biomarkers (miRs-21, 31, and 210), which could diagnose lung cancer with a higher sensitivity compared with sputum cytology.<sup>18</sup> Therefore, the analysis of sputum miRNAs



may provide a noninvasive tool for facilitating diagnosing NSCLC.

However, some subjects, particularly former smokers, are unable to spontaneously expectorate sputum, presenting a major obstacle in cytological and molecular diagnosis of lung cancer in sputum.<sup>19,20</sup> To overcome this clinical challenge, we previously used Lung Flute to collect sputum.<sup>19</sup> The Lung Flute is a Food and Drug Administration (FDA)-cleared noninvasive, self-powered audio, and drug-free plastic device that was initially used as a therapeutic tool for numerous chronic pulmonary conditions.<sup>21</sup> It can generate sound waves, which is created by exhalation. Sound waves increase the clearance of mucus, thus making discharges of mucus easily expelled through coughing. Using the Lung Flute, we successfully collected sputum within 20 minutes from individuals who cannot expectorate sputum.<sup>19</sup> No adverse effect was observed.<sup>19</sup>

The objective of this study is to further evaluate the performance of the Lung Flute by comparing the characteristics of parallel samples collected with and without the Lung Flute and the potential usefulness for diagnosis of lung cancer. Our results show that sputum collected by the Lung Flute exhibit comparable features as spontaneously expectorated sputum, and are of low respiratory origin without contamination from other sources. Using the Lung Flute may improve cytological and molecular analyses of sputum for the diagnosis of NSCLC.

## Materials and Methods

**Patients and sample collection and preparation.** The study was approved by the Institutional Review Boards of the University of Maryland Medical Center and the Baltimore Veterans Affairs (VA) Medical Center. All patients with lung cancer and control subjects were selected and consented when they visited the clinics of the Division of Pulmonary and Critical Care in the two medical centers. Final clinical diagnoses for the lung cancer patients were confirmed by histopathologically examining biopsy or surgically resected tissue specimens. The histopathological classification and staging were decided based on the Tumour, Node, Metastases (TNM) classification as previously described.<sup>15–18</sup> Control individuals were subjects aged 55–74 who had more than 30 pack-year smoking history and no prior history of any cancer. The smokers who had quit within the previous 15 years were considered as former smokers. Furthermore, all control individuals remained cancer free for a minimum 2-year follow-up. This research complied with the principles of the Declaration of Helsinki.

**Sputum collection and preparation and sputum cytology.** Collecting sputum was performed before any treatment regimen (eg, surgery, preoperative adjuvant chemotherapy, and radiotherapy). To reduce food and salivary contamination in sputum, the participants rinsed their mouth out with water and gargled three times before using the Lung Flute or spontaneously expectorating. Sputum was first collected into a sterile container by spontaneously coughing

as described in our previous studies.<sup>13,14,16–18,22–26</sup> After 1 hour, the participants were asked to rinse their mouth out with water three times again and instructed to use the Lung Flute (Medical Acoustics, Buffalo, NY, USA) for sputum sampling.<sup>19,21,27</sup> Briefly, the subjects were asked to blow their nose and rinse their mouth to further diminish contamination of squamous cells from postnasal drip and mouth, blow out through Lung Flute, and cough up sputum into a sterilized cup. The collected sputum was immediately put on ice in dithiothreitol (Sigma-Aldrich Corporation, Saint Louis, MO, USA). The sputum samples were then centrifuged at 800 *g* for 10 min. The cell pellet was mixed with phosphate-buffered saline solution (PBS) (Sigma-Aldrich). Cytospin slides were prepared and underwent Papanicolaou staining for evaluating whether the specimens were representative of deep bronchial cells. Furthermore, May-Grünwald-Giemsa was used to stain the slides for cell counting. Cytological diagnosis was performed on the cytospin slides using the classification of Saccomanno et al.<sup>28</sup> Positive cytology included both carcinoma in situ and invasive carcinoma.<sup>29</sup> Finally, the cell pellets were washed in PBS again, centrifuged for 10 min at 800 *g*, and then kept at –80 °C until use.

**Isolation of RNA and analysis of miRNAs by real-time quantitative reverse transcription–polymerase chain reaction.** RNA was isolated from the sputum samples by using a protocol developed in our previous studies.<sup>13–18</sup> The purity and concentration of RNA and RNA integrity were determined by using the methods as described in our previous reports.<sup>15–18</sup> Three miRNAs, miRs-21, 31, and 210, were previously identified as potential sputum miRNA biomarkers for lung cancer.<sup>15–18</sup> In this study, the three miRNAs were evaluated for the expression in sputum by using quantitative reverse transcription–polymerase chain reaction (qRT-PCR) with Taqman miRNA assays (Applied Biosystems, Foster City, CA, USA).<sup>13–18</sup> U6 was used as an internal control gene to normalize threshold cycle (Ct) values of the three miRNAs. We performed all assays in triplicates. Each experiment included one no-template control and two interplate controls.

**Statistical analysis.** Continuous variables were compared using *t*-tests, and categorical variables were compared using Fisher's exact test. Pearson's correlation coefficient tests with multivariate regression analysis were used to evaluate the relations between expressions of the miRNAs and characteristics of the cases and controls. Receiver operating characteristic curve and the area under the curve (AUC) analyses were employed to determine performance of miRNAs.<sup>30</sup>

## Results

**Subject characteristics.** The 56 lung cancer patients had a median age of 68.4 years (Table 1). Of them, 36 (64.3%) were men and 39 (69.3%) were White Americans. The lung cancer cases were stage I NSCLC. The cancer patients were smokers with a median of 38.3 pack-years of smoking. Among the 56 NSCLC cases, 40 (71.4%) were current smokers, while

**Table 1.** The demographic and clinical variables of NSCLC patients and cancer-free smokers.

	73 CANCER-FREE SMOKERS	56 NSCLC PATIENTS
Age, Median (SD)	67.8(SD 9.3)	68.4(9.6) <sup>†</sup>
<b>Gender</b>		
Female	26 (35.6%)	20 (35.7%) <sup>†</sup>
Male	47 (64.4%)	36 (64.3%) <sup>†</sup>
<b>Race</b>		
African American	21 (28.8%)	17 (30.4) <sup>†</sup>
White	52 (71.2%)	39(69.3%) <sup>†</sup>
<b>Smoking status</b>		
Pack-years, Median (SD)	36.4 (SD 11.6)	38.3 (SD 12.7) <sup>†</sup>
Current smokers	52 (71.2%)	40 (71.4%) <sup>†</sup>
Former smokers*	21(28.8%)	16 (28.6%) <sup>†</sup>
Stage		All are stage I
<b>Historical types of</b>		
AC		31 (55.3%)
SCC		25 (44.7%)

**Notes:** \*Former smokers are individuals who quit smoking within the last 15 years. <sup>†</sup>All  $P > 0.05$ .

**Abbreviations:** NSCLC, non-small-cell lung cancer; SD, standard deviation; AC, adenocarcinoma; SCC, squamous cell carcinoma.

16 (28.6%) were former smokers. Thirty-one (55.3%) were adenocarcinoma (AC) and 25 (44.7%) were squamous cell carcinoma (SCC). The 73 cancer-free smokers had a median age of 67.8 years and a median of 36.4 pack-years of smoking. Forty-seven (64.4%) were men and 52 (71.2%) were White Americans. Fifty-two (71.2%) were present smokers, while 21 (28.8%) were former smokers. In total, there were 92 current smokers and 37 former smokers in all cases and controls. There was no statistically significant difference of the age, race, and smoking status between the two groups (all  $P > 0.05$ ).

**Collection of sputum by using spontaneous coughing and the Lung Flute.** All 92 current smokers, including 40 NSCLC cases and 52 controls, could easily cough sputum. When using the Lung Flute, they also produced sputum. Of the 37 former smokers (16 NSCLC patients and 21 cancer-free controls), only 7 (18.9%) were able to spontaneously expectorate sputum; however, 30 (81.8%) could not spontaneously expectorate sputum. Of the seven former smokers who were able to spontaneously expectorate sputum, there were three NSCLC patients and four controls. The 30 former smokers, who could not spontaneously expectorate sputum, included 13 NSCLC patients and 17 controls. If using the Lung Flute, however, all the 37 former smokers were able to produce sputum. Overall, the success rate of collecting sputum was 76.7% (92/129) for spontaneous coughing, whereas it was 100% (129/129) for the Lung Flute ( $P = 0.01$ ) (Table 2). The success rate of either spontaneous coughing or using the Lung Flute was not associated with cancer status. Therefore, the use of the Lung Flute could obtain sputum samples from cancer patients, cancer-free smokers, current smokers, or former smokers who were not able to spontaneously expectorate sputum. Only 11 of all the 129 participants had slight sore throat or faintness

after using the Lung Flute. The minor distresses disappeared within 1 hour.

**Comparison of characteristics of sputum samples collected by spontaneous coughing and the Lung Flute.** As shown in Table 2, the median volume of sample collected by spontaneous coughing was 2.7 mL, while the median volume of sample obtained by the Lung Flute was 2.6 mL ( $P = 0.46$ ). The median cell number per milliliter was  $2.6 \times 10^7$  and  $2.5 \times 10^7$  in sputum collected by spontaneous coughing and sputum collected by the Lung Flute, respectively ( $P = 0.62$ ). Samples were considered to be of lower respiratory origin, if they had less than 4% oral squamous epithelial cells and more than 50% alveolar macrophages. Based on the criteria, all sputum samples collected by the two approaches except one were expelled from the lower respiratory tract. This sputum sample was collected by spontaneous coughing and had more than 4% oral squamous cells and less than 50% alveolar macrophages (Fig. 1A). The individual was asked to spontaneously cough sputum again on the next day. The repeated process produced 1.2 mL of sputum that had below 4% oral squamous cells and more than 50% alveolar macrophages, and thus was suitable for the study. Overall, oral squamous epithelial cells was 2.3% in sputum collected by spontaneous coughing and 2.2% in sputum collected by the Lung Flute ( $P = 0.37$ ). Furthermore, there were 56% alveolar macrophages in sputum collected by spontaneous coughing and 53% alveolar macrophages in sputum collected by the Lung Flute ( $P = 0.19$ ) (Fig. 1B). Therefore, sputum collected by the Lung Flute displayed comparable features as spontaneously expectorated sputum (Table 2) and had no contamination of squamous cells from postnasal drip and mouth. In addition, there was no statistical difference of sputum volume and cell populations in the specimens collected

**Table 2.** Sputum collected by the Lung Flute has comparable characteristics as spontaneously expectorated sputum.


	SPONTANEOUSLY COUGHING	LUNG FLUTE	P-VALUE
<b>Successful rate of sputum sampling</b>			
All smokers	76.70%	100%	0.01
Current smokers	100%	100%	1
Former smokers	18.90%	100%	<0.01
Volume of sputum (median, SD)	2.7 ml (1.5)	2.6 ml (1.6)	0.46
Cell numbers per ml (median, SD)	2.6 (0.4) × 10 <sup>7</sup> cells	2.5 (0.3) × 10 <sup>7</sup> cells	0.62
% oral squamous cells (median, SD)	2.3 (0.2)	2.2 (0.3)	0.37
% alveolar macrophages (median, SD)	56 (9)	53 (7)	0.19

from current smokers versus former smokers (all  $P > 0.05$ ) (Supplementary Table 1).

**Comparison of diagnostic efficiency of cytology and molecular analysis in sputum collected by spontaneous coughing and the Lung Flute.** Cytology had 46.51% sensitivity and 89.29% specificity for the identification of NSCLC in sputum collected by the Lung Flute, 46.43% sensitivity and 89.04% specificity in sputum collected by spontaneous coughing (all  $P > 0.05$ ). Therefore, there was no different performance of sputum cytology in the samples collected by the two approaches.

qRT-PCR for quantification of miRNA expression was successfully undertaken in the specimens, since all three miRNAs had  $\leq 30$  Ct values in each sputum sample. The three miRNAs displayed a significantly different level between NSCLC patients and control subjects (all  $P < 0.01$ ) (Table 3) (Fig. 2). Furthermore, the individual genes displayed 0.77–0.85 AUCs (confidence interval [CI], 0.67–0.93) in the sputum samples collected by the Lung Flute (Table 3), and 0.78–0.82 AUCs (CI, 0.73–0.91) in the samples collected

by spontaneous coughing for the identification of NSCLC (Supplementary Table 2) (all  $P > 0.05$ ). The three miRNAs analyzed in combination had an AUC of 0.91 (CI, 0.84–0.97) in sputum collected by the Lung Flute (Table 3) and an AUC of 0.90 (CI, 0.82–0.96) in the samples collected by spontaneous coughing (Supplementary Table 2) ( $P > 0.05$ ). The combination of the three miRNAs in the sputum samples by the Lung Flute produced a higher AUC compared with any single miRNA used alone (all  $P < 0.05$ ) (Fig. 3). Subsequently, the three miRNAs used together created 83.93% sensitivity and 87.67% specificity in sputum collected by the Lung Flute for the identification of NSCLC (Table 3). Similarly, combined use of the three miRNAs in sputum collected by spontaneously coughing generated a higher AUC (0.90; CI, 0.82–0.96) compared with any single miRNA (0.73–83; CI, 0.73–0.91) (all  $P < 0.05$ ). As a result, the panel of three miRNAs produced a sensitivity of 83.72% and a specificity of 87.50% for diagnosis of NSCLC in sputum collected by spontaneous coughing. In addition, Pearson's coefficients showed a significant correlation between the molecular results generated



**Figure 1.** Cytological examination of sputum (Papanicolaou's stain; original magnification ×40). **(A)** A poorly collected sputum sample that contains many oral squamous epithelial cells (indicated by opened arrows) and few respiratory epithelial cells (indicated by closed arrows). The oral squamous epithelial cells are large, flat, platelike cells with copious clear cytoplasm, relatively small dense nucleus, and sharp cellular boundaries. **(B)** A sputum sample is of lower respiratory origin, since it has less than 4% oral squamous epithelial cells and more than 50% alveolar macrophages (indicated by arrowheads) and respiratory epithelial cells (indicated by closed arrows). Respiratory epithelial cells are long slender cells with cilia at one end and nucleus located at the base of cell and a slender tail at the end opposite to the cilia. Alveolar macrophages are dense cells with a single nucleus located to one side of the cells.

**Table 3.** Expression levels of miRNAs in sputum collected by the Lung Flute from NSCLC patients and cancer-free smokers.

miRNAs	MEAN (SEM) IN 73 CONTROLS	MEAN (SEM) IN 56 NSCLC PATIENTS	P-VALUE	AUC (95%CI)	SENSITIVITY	SPECIFICITY
miR-31	0.49 (0.68)	3.27 (0.54)	<0.01	0.77 (0.67 to 0.86)	64.26	83.93
miR-21	7.62 (1.53)	51.08 (6.32)	<0.01	0.81 (0.72 to 0.89)	75.00	80.28
miR 210-	7.64 (1.10)	70.02 (8.11)	<0.01	0.85 (0.78 to 0.93)	82.76	78.56
Combined three miRNAs			<0.01	0.91 (0.84 to 0.97)	83.93	87.67

**Abbreviations:** NSCLC, non-small-cell lung cancer; SEM, the standard error of the mean; AUC, the area under receiver operating characteristic curve; CI, confidence interval.

from sputum samples collected by spontaneous coughing and sputum obtained by the Lung Flute ( $r = 0.849$ ,  $P = 0.001$ ). Therefore, there was no different performance of the sputum miRNA biomarkers for the diagnosis of NSCLC in the samples collected by the two approaches.


Comparison of sputum cytology and miRNA panel in sputum collected by the Lung Flute showed that the sputum miRNA biomarkers had a higher sensitivity (83.93%) compared with sputum cytology (46.51%), while maintaining a similar specificity (87.67% vs. 89.29%,  $P = 0.09$ ). Furthermore, the expression of miR-21 in sputum was closely related with AC ( $P < 0.05$ ), whereas miR-210 was associated with SCC ( $P < 0.05$ ). However, the three biomarkers used together did not exhibit special association with a particular histological type of the NSCLC cases. The changes of the three miRNAs in sputum had no association with age, gender, and ethnicity of the participants (all  $P > 0.05$ ) but SPN size ( $P < 0.05$ ). The level of miR-31 expression was related with the smoking status of cancer cases ( $P = 0.03$ ).

## Discussion


Very often some subjects, particularly former smokers, are unable to spontaneously expectorate sputum, presenting a major clinical challenge in developing sputum biomarkers. Overcoming this difficulty is becoming more clinically important, since lung cancer is now predominant among former rather than current smokers, with the decline in smoking.<sup>2</sup> To address the challenge, we previously used Lung Flute for sputum sampling and found that Lung Flute could be

used to collect sputum from persons who could not spontaneously cough sputum.<sup>19</sup> To extend our previous study, here we assess the diagnostic performance of the Lung Flute by evaluating the characteristics of the parallel samples collected by using the two different approaches in smokers. Using the Lung Flute, we not only collect sputum from all current smokers, but the former smokers who cannot spontaneously cough sputum. Furthermore, the collected sputum samples by the Lung Flute have at least  $2 \times 10^7$  cells/mL, suggesting the sputum samples have enough cell number for downstream cytological and molecular analysis. In addition, each sputum sample has less than 4% oral squamous cells and more than 50% alveolar macrophages. The findings strongly suggest that the sputum samples are of low respiratory origin without contamination from other sources, eg, saliva. Moreover, our head-to-head comparison shows no statistical diagnostic difference of sputum cytology for lung cancer in specimens collected by the two approaches. Sputum collected by the Lung Flute has equal features as spontaneously expectorated sputum. The Lung Flute was well tolerated by all participants. Altogether, the use of Lung Flute may overcome one of the obstacles in cytological diagnosis of NSCLC by efficiently collecting appropriate sputum from smokers.

Molecular analysis of sputum can identify the cells that contain cancer-related abnormalities and might be more sensitive than cytology for diagnosis of lung cancer.<sup>8</sup> We recently developed a panel of three sputum miRNA biomarkers (miRs-21, 31, and 210) for lung cancer.<sup>18</sup> In this current study, we successfully validate the three miRNA biomarkers in sputum



**Figure 2.** The expression levels of the three miRNAs in sputum collected by the Lung Flute from 56 patients diagnosed with stage I NSCLC and 73 cancer-free smokers. Horizontal lines denote mean values. The three miRNAs (A–C) show statistical significance of expression levels between NSCLC patients and cancer-free smokers (all  $P < 0.01$ ).



**Figure 3.** Receiver-operating characteristic (ROC) curve analysis of expression levels of the three miRNAs in sputum collected by the Lung Flute in 56 patients diagnosed with stage I NSCLC and 73 cancer-free smokers. The AUC for each miRNA conveys its accuracy for differentiation of NSCLC patients and cancer-free smokers in terms of sensitivity and specificity. The individual genes produce 0.77–0.85 AUC values (A–C), being significantly lower than 0.91 AUC created by combined use of the three genes (D) (all  $P < 0.05$ ).

collected by the Lung Flute using a different cohort of cases and controls. Furthermore, the analysis of the miRNA biomarkers in sputum collected by the Lung Flute had a greater sensitivity than sputum cytology, while keeping a similar specificity, thus confirming our previous findings.<sup>13,18</sup> In addition, there is a similar diagnostic performance of the miRNA biomarkers in sputum collected by the two different approaches. Therefore, sputum collected by the Lung Flute may have equivalent clinical value as spontaneously expectorated sputum in molecular diagnosis of lung cancer.

There are some weaknesses in the present study. First, the sample size of cases and controls is not large enough to comprehensively validate the utility of the Lung Flute for sputum sampling. We are planning a larger scale validation study for the Lung Flute across multiple centers in a population screened by LDCT. Second, although showing promise, the panel of three sputum miRNA biomarkers only has 83.93% sensitivity and 87.67% specificity for lung cancer. Our ongoing efforts are to identify additional miRNA biomarkers that can be added to the three miRNAs to improve diagnosis of lung cancer. Third, we did not find statistical difference of sputum volume and cell populations in the specimens collected by the two approaches. We also did not observe statistical variance of the parameters in sputum samples of former versus current

smokers. However, whether there is any difference in the biological characteristics of sputum samples collected by the two approaches as well as sputum samples of current versus former smokers needs to be investigated.

In summary, sputum collected by the Lung Flute has comparable characteristics as spontaneously expectorated sputum. The use of the Lung Flute may overcome one of the obstacles in the development of sputum biomarkers by safely and efficiently obtaining appropriate sputum from individuals, particularly prior smokers. Nonetheless, carrying out a multi-center clinical trial to validate the Lung Flute and the sputum miRNA biomarkers for lung cancer diagnosis in a large and prospective population is required.

### Author Contributions

Conceived and designed the experiments: JS, NA, MAG, HZ, FJ. Analyzed the data: JS, NA. Wrote the first draft of the manuscript: FJ. Contributed to the writing of the manuscript: SAS. Agree with manuscript results and conclusions: JS, NA, MAG, HZ, SAS, FJ. Jointly developed the structure and arguments for the paper: SAS. Made critical revisions and approved final version: JS, NA, MAG, HZ, SAS, FJ. All authors reviewed and approved of the final manuscript.



## Supplementary Material

**Supplementary Table 1.** Sputum volume and cell populations in samples collected by Lung Flute in current and former smokers.

**Supplementary Table 2.** Levels of miRNAs in sputum collected by spontaneous coughing from NSCLC patients and cancer-free smokers.

## REFERENCES

1. American Cancer Society. *Cancer Facts & Figures*. Atlanta, GA: The Society;v. 2015.
2. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. *Chest*. 2005;128:452–62.
3. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*. 2011;365:395–409.
4. Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014;160:330–8.
5. Patz EF Jr, Pinsky P, Gatsonis C, et al; NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. *JAMA Intern Med*. 2014;174:269–74.
6. Church TR, Black WC, Aberle DR, et al; National Lung Screening Trial Research Team. Results of initial low-dose computed tomographic screening for lung cancer. *N Engl J Med*. 2013;368:1980–91.
7. MacMahon H, Austin JH, Gamsu G, et al; Fleischner Society. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. *Radiology*. 2005;237:395–400.
8. Thunnissen FB. Sputum examination for early detection of lung cancer. *J Clin Pathol*. 2003;56:805–10.
9. Frost JK, Ball WC Jr, Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. *Am Rev Respir Dis*. 1984;130:549–54.
10. Kennedy TC, Hirsch FR. Using molecular markers in sputum for the early detection of lung cancer: a review. *Lung Cancer*. 2004;45:21–7.
11. Hubers AJ, Prinsen CF, Sozzi G, Witte BI, Thunnissen E. Molecular sputum analysis for the diagnosis of lung cancer. *Br J Cancer*. 2013;109:530–7.
12. Suzuki M, Yoshino I. Aberrant methylation in non-small cell lung cancer. *Surg Today*. 2010;40:602–7.
13. Shen J, Liao J, Guarnera MA, et al. Analysis of microRNAs in sputum to improve computed tomography for lung cancer diagnosis. *J Thorac Oncol*. 2014;9:33–40.
14. Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. *J Cancer Res Clin Oncol*. 2014;140:145–50.
15. Yu L, Todd NW, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. *Int J Cancer*. 2010;127:2870–8.
16. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. *Mod Pathol*. 2010;23:1157–64.
17. Xie Y, Todd NW, Liu Z, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. *Lung Cancer*. 2010;67:170–6.
18. Xing L, Su J, Guarnera MA, et al. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. *Clin Cancer Res*. 2015;21:484–9.
19. Anjuman N, Li N, Guarnera M, Stass SA, Jiang F. Evaluation of lung flute in sputum samples for molecular analysis of lung cancer. *Clin Transl Med*. 2013;2:15.
20. Comandini A, Rogliani P, Nunziata A, Cazzola M, Curradi G, Saltini C. Biomarkers of lung damage associated with tobacco smoke in induced sputum. *Respir Med*. 2009;103:1592–613.
21. Fujita A, Murata K, Takamori M. Novel method for sputum induction using the lung flute in patients with suspected pulmonary tuberculosis. *Respirology*. 2009;14:899–902.
22. Yu L, Shen J, Mannoor K, Guarnera M, Jiang F. Identification of ENO1 as a potential sputum biomarker for early-stage lung cancer by shotgun proteomics. *Clin Lung Cancer*. 2014;15:372–8.e1.
23. Jiang F, Todd NW, Li R, Zhang H, Fang H, Stass SA. A panel of sputum-based genomic marker for early detection of lung cancer. *Cancer Prev Res (Phila)*. 2010;3:1571–8.
24. Jiang F, Todd NW, Qiu Q, Liu Z, Katz RL, Stass SA. Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. *Lung Cancer*. 2009;66:58–63.
25. Katz RL, Zaidi TM, Fernandez RL, et al. Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer. *Mod Pathol*. 2008;21:950–60.
26. Qiu Q, Todd NW, Li R, et al. Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. *Cancer*. 2008;114:275–83.
27. Doumit M, Jaffe A. Use of the lung flute for sputum induction in children with cystic fibrosis: a pilot study. *Pediatr Pulmonol*. 2015;50(4):340–3.
28. Saccomanno G, Saunders RP, Archer VE, Auerbach O, Kuschner M, Beckler PA. Cancer of the lung: the cytology of sputum prior to the development of carcinoma. *Acta Cytol*. 1965;9:413–23.
29. Varela-Garcia M, Kittelson J, Schulte AP, et al. Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. *Cancer Detect Prev*. 2004;28:244–51.
30. Pepe MS, Feng ZD, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. *J Natl Cancer Inst*. 2008;100:1432–8.